On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), for CML (Chronic Myeloid Leukemia) was approved by the FDA after the Novartis patent expiration and will become available for the first time in the United States through Sun Pharmaceuticals.
According to a 2015 report by the National Alliance of Caregivers, approximately 43.5 million adults in the United States provided unpaid care to an adult or child in 2015. Caregivers come from diverse demographic [...]
Dear LRG Community, Thanks to our: Caregivers, the unsung heroes who care for and give to our patients every day Research team, who tirelessly reach for our mission to find a cure Donors, who [...]
The Life Raft Group is pleased to announce the release of the eighth issue of The GIST Cancer Journal, the official journal of the Life Raft Group and the first academic journal devoted solely [...]
Fall and winter mark the beginning of the flu season which is a concern for GIST patients. Though the weather is extraordinarily warm in this early winter, it does not mean the temperatures [...]
In a recent release from the Translational Genomics Research Institute (TGen), it was reported that researchers have discovered that by analyzing circulating tumor DNA (ctDNA) through liquid biopsy that a patient's cancer can be tracked [...]
The 7th Annual Partnering for Cures meeting hosted by FasterCures was held Nov. 1-3 in NYC with more than 750 movers and shakers from patient groups, pharma, academia, government and industry. Some notable participants included: [...]
A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]
It has been a long journey since that day Melinda and I walked out of my Dallas oncologist’s office in May, 2000 knowing that I had a rare, then untreatable cancer. Now, it has [...]
Immunotherapy is a promising area in cancer research and in emerging treatments. Several new studies highlight the role that gut microbes may play in the efficacy of immunotherapy treatments.In a recent article in the Atlantic, [...]
